Back to Press Releases  |  Previous  |  Next

U.S. Navy Reaches Agreement to Purchase QBC STAR Hematology Analyzers for Use on its Surface Fleet

Port Matilda, Pennsylvania, August 10, 2010 -  QBC Diagnostics was awarded one of the largest contracts in company history, as the United States Navy has agreed to install QBC STAR hematology analyzers on surface ships throughout the world.

The QBC STAR provides users a 9-parameter complete blood count through its patented dry hematology approach, which eliminates the need for liquid reagents.  Because of this technology, as well as the unit's small footprint and internal calibration system, the STAR can be transported easily and provide accurate patient results within minutes.

Ken Moscone, President and CEO of QBC Diagnostics, said, "We are incredibly pleased to bring the benefits of the QBC STAR to the men and women of the United States Navy.  The STAR possesses many features that will help to keep our servicemen and women healthy as they protect our country."

"Our line of hematology products are especially well-suited for use in the military environment," Moscone continued.  "With one-button operation, no start-up requirements, and the use of simple blood collection tubes, the STAR is robust, designed to go anywhere and provide results quickly.  Unlike liquid reagents, dry QBC technology is not adversely affected by the pitch and roll of a ship, making it especially well-suited for use on Navy vessels."

For more information on the QBC STAR, please consult the QBC Diagnostics website at http://www.qbcdiagnostics.com/products/hema/star/fab.asp.

Next: QBC Diagnostics Continues Its Support of Nyaya Health Mission

About QBC Diagnostics
QBC Diagnostics is a privately held company headquartered in Port Matilda, Pennsylvania.  The company manufactures a line of complete blood count analyzers and fluorescence microscopy products.  Additional information can be found by visiting the company website (www.qbcdiagnostics.com) or by calling 877-231-3115.  Follow QBC on Twitter or Facebook for further updates.